Sanofi, GSK tout 72% Omi­cron ef­fi­ca­cy in PhI­II tri­al of next-gen, bi­va­lent shot — with an eye to year-end roll­out

Some­times, be­ing late can give you an ad­van­tage.

That’s what Sanofi and GSK are try­ing to say as the Big Phar­ma part­ners re­port pos­i­tive re­sults from a late-stage tri­al of their next-gen bi­va­lent Covid-19 vac­cine, which was de­signed to pro­tect against both the orig­i­nal strain of the SARS-CoV-2 virus and the Be­ta vari­ant. Specif­i­cal­ly, against Omi­cron, they note, the vac­cine de­liv­ered 72% ef­fi­ca­cy in all adults and 93.2% in those pre­vi­ous­ly in­fect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER